Ausgabe 6/2005
Inhalt (15 Artikel)
A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers
Mireille V. Cantarini, Merran P. Macpherson, Anna L. Marshall, Anna V. Robinson, Christopher J. Bailey
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer
Pierpaolo Correale, Fabio Fulfaro, Stefania Marsili, Giuseppe Cicero, Eugenia Bajardi, Chiara Intrivici, Giuseppe Vuolo, Antonio Ferdinando Carli, Michele Caraglia, Salvatore Del Prete, Ettore Greco, Nicola Gebbia, Guido Francini
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models
Qingyu Zhou, Malini Olivo, Karen Yee Kar Lye, Shirley Moore, Amarnath Sharma, Balram Chowbay
The absolute bioavailability of oral vinorelbine in patients with solid tumors
Richard M. Lush, Jeannine S. McCune, Leticia Tetteh, John A. Thompson, J. J. Mahany, Linda Garland, A. Benjamin. Suttle, Daniel M. Sullivan
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ
Keisuke Yamaguchi, Mark D. Richardson, Darrell D. Bigner, Madan M. Kwatra
Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis
Z. Nikolic-Tomasevic, S. Jelic, J. Cassidy, I. Filipovic-Ljeskovic, Z. Tomasevic
Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous Vasopressin in non-resectable pancreas cancer
M. Öman, S. Lundqvist, B. Gustavsson, LO. Hafström, P. Naredi
The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel
Naoki Agata, Hiroko Nogi, Michael Bamberg, Michael Milhollen, Minying Pu, Steven Weitman, Surender Kharbanda, Donald Kufe
Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells
John Michalakis, Spyros D. Georgatos, John Romanos, Helen Koutala, Vassilis Georgoulias, Dimitris Tsiftsis, Panayiotis A. Theodoropoulos
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
Grace K. Dy, Sumithra Mandrekar, Prema P. Peethambaram, Scott H. Okuno, Gary C. Croghan, Lorelei J. Hanson, Alfred Furth, Alex A. Adjei
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice
Christopher L. Morton, Lisa Iacono, Janice L. Hyatt, Kody R. Taylor, Pamela J. Cheshire, Peter J. Houghton, Mary K. Danks, Clinton F. Stewart, Philip M. Potter
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance
Elizabeth R. Glaze, Amy L. Lambert, Adaline C. Smith, John G. Page, William D. Johnson, David L. McCormick, Alan P. Brown, Barry S. Levine, Joseph M. Covey, Merrill J. Egorin, Julie L. Eiseman, Julianne L. Holleran, Edward A. Sausville, Joseph E. Tomaszewski
Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients
Seiichirou Hoshino, Yuuichi Yamashita, Takafumi Maekawa, Takayuki Shirakusa
Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase i study
Athanasios Athanasiadis, George Roussos, Thomas Papakostoulis, Daniela-Carmen Athanasiadou, George P. Stathopoulos
Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy
C. Kirszberg, V. M. Rumjanek, M. A. M. Capella